Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Russell's viper venom factor X activator (RVV-X) is a major, highly toxic zinc-dependent metalloproteinase found in the venom of Russell's viper (*Daboia russelii*). It belongs to the P-IIId class of snake venom metalloproteinases and is responsible for activating blood coagulation factor X by specific proteolytic cleavage, thereby initiating rapid clot formation, disseminated intravascular coagulation, and widespread tissue damage. The toxin contributes to multiple systemic pathologies following envenomation, making it a major drug and diagnostic target for antivenom development and laboratory detection of clotting disorders. Other minor toxins (such as various phospholipase A2 isoforms) exist in the venom, but RVV-X is the canonical therapeutic target.
RVV-X acts through enzymatic cleavage and activation of factor X at Arg194-Ile195. This is a Zn^2+-dependent hydrolysis reaction that initiates the coagulation cascade via direct factor X activation.
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Russell's viper venom factor X activator (RVV-X).